Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Middleby's Ss Brewtech Buyout Enhances Beverage Portfolio

Published 06/17/2019, 09:42 PM
Updated 07/09/2023, 06:31 AM

The Middleby Corporation (NASDAQ:MIDD) announced that it has successfully completed the acquisition of Ss Brewtech. However, the financial terms of the transactions have been kept under wraps.

Founded in 2013, Ss Brewtech is one of the leading beverage equipment makers and the finest player in the craft brewing industry. Based in Santa Ana, CA, this company generates total annual revenues of $20 million.

Inside the Headlines

The Ss Brewtech buyout is believed to be a strategic fit for Middleby. It will create solid growth opportunities for Middleby backed by the increasing fondness for on-site brewing, mainly in restaurants and bars. This apart, the addition of more than 30 employees will be beneficial.

Middleby noted that Ss Brewtech will work independently as its business unit.

Glimpse of Middleby’s Inorganic Initiatives

We believe that the above-mentioned transaction is consistent with Middleby’s policy of acquiring businesses for attracting more customers and gaining access to various regions and product lines.

In April 2019, the company successfully completed the acquisition of Cooking Solutions Group of Standex International Corporation (NYSE:SXI) . Also, the company acquired Newton, MA-based Powerhouse Dynamics, Inc.

Prior to these, Middleby added EVO America and Crown Food Service Equipment to its portfolio in December 2018. Further, M-TEK Corporation was acquired in October 2018, Taylor Company was bought in June, Josper S.A. in May, Firex S.r.l., Ve.Ma.C S.r.l. in April, certain assets of JoeTap in March and Hinds-Bock Corporation in February.

Notably, these strategic buyouts drove Middleby’s sales by 16.1% in 2018 and by 17.2% in the first quarter of 2019. In the quarters ahead, these acquired assets are likely to boost Middleby’s top-line performance.

Zacks Rank & Key Picks

With a market capitalization of nearly $7.3 billion, Middleby currently carries a Zacks Rank #3 (Hold). Notably, solid product portfolio, synergistic gains from buyouts, strength in Viking business, efforts to broaden technological and manufacturing capabilities, and healthy product demand bode well for the company. However, it faces risks from high costs and operating expenses, unfavorable movements in foreign currencies and increased debts.

In the past 60 days, Middleby’s earnings estimates for 2019 have been lifted by one firm and lowered by two, while the same for 2020 has been raised by one firm and decreased by three. Currently, the Zacks Consensus Estimate is pegged at $6.92 for 2019 and $7.77 for 2020, reflecting a decline of 0.3% for 2019 and 0.5% for 2020.

The Middleby Corporation Price and Consensus

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The Middleby Corporation price-consensus-chart | The Middleby Corporation Quote

Shares of Middleby have increased 0.8% compared with the industry’s 3.5% growth in the past three months.



Two better-ranked stocks in the same industry are Chart Industries, Inc. (NASDAQ:GTLS) and DXP Enterprises, Inc. (NASDAQ:DXPE) . While Chart Industries sports a Zacks Rank #1 (Strong Buy), DXP Enterprises carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

In the past 30 days, earnings estimates for Chart Industries and DXP Enterprises improved for the current year. Further, average earnings surprise for the last four quarters was positive 16.56% for Chart Industries and 48.47% for DXP Enterprises.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



DXP Enterprises, Inc. (DXPE): Free Stock Analysis Report

The Middleby Corporation (MIDD): Free Stock Analysis Report

Standex International Corporation (SXI): Free Stock Analysis Report

Chart Industries, Inc. (GTLS): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.